A Randomized, Double-blind, Parallel, Placebo-controlled, Multiple Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Clinical Effect of AMG 557 in Systemic Lupus Erythematosus (SLE) Subjects With Active Lupus Arthritis
Latest Information Update: 12 Mar 2018
At a glance
- Drugs Prezalumab (Primary)
- Indications Arthritis; Systemic lupus erythematosus
- Focus Adverse reactions; Pharmacodynamics; Therapeutic Use
- Sponsors Amgen
- 07 Mar 2018 Results assessing safety, efficacy and immunogenicity published in the Arthritis and Rheumatology
- 17 Jun 2017 Primary endpoint (Lupus Arthritis Response Rate) has not been met as per the results presented at the 18th Annual Congress of the European League Against Rheumatism
- 17 Jun 2017 Results presented at the 18th Annual Congress of the European League Against Rheumatism